Knight Therapeutics (TSE:GUD) Shares Up 0.2% – Should You Buy?

Shares of Knight Therapeutics Inc. (TSE:GUD) shot up 0.2% on Tuesday . The stock traded as high as C$6.23 and last traded at C$6.15. 43,350 shares traded hands during trading, a decline of 55% from the average session volume of 96,539 shares. The stock had previously closed at C$6.14.

Knight Therapeutics Price Performance

The stock has a market capitalization of C$625.52 million, a price-to-earnings ratio of -157.50, a P/E/G ratio of -1,013.50 and a beta of 0.15. The company has a quick ratio of 1.79, a current ratio of 2.62 and a debt-to-equity ratio of 13.86. The stock has a fifty day moving average of C$6.08 and a 200-day moving average of C$6.05.

Knight Therapeutics (TSE:GUD) last released its quarterly earnings data on Thursday, March 19th. The company reported C$0.09 earnings per share for the quarter. Knight Therapeutics had a negative net margin of 0.84% and a negative return on equity of 0.45%. The company had revenue of C$133.20 million for the quarter. On average, equities research analysts predict that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.